

## Tiiu Noobel

---

**From:** Jakimiuk Marta <marta.jakimiuk@ema.europa.eu>  
**Sent:** teispäev, 3. märts 2026 13:25  
**To:** Tiiu Noobel  
**Cc:** Jenas Kärolin  
**Subject:** RE: Estonia - 2026-02-16 - Nomination invitation letter for CAT alternate  
**Attachments:** Estonia - 2026-02-16 - Nomination invitation letter for CAT alternate - Pille Saalik\_.pdf

**Importance:** High

**Follow Up Flag:** Follow up  
**Flag Status:** Flagged

Dear Tiiu Noobel,

Further to the below correspondence, attached please find the nomination letter for Estonia.

Kind regards,

**Marta Jakimiuk**  
Experts and Declarations of Interests Management  
Meeting Secretariat Office  
Committees and Quality Assurance Department



[European Medicines Agency](#)  
Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands  
Tel. +31 (0)88 781 8354  
[ExpertsDB@ema.europa.eu](mailto:ExpertsDB@ema.europa.eu) | [www.ema.europa.eu](http://www.ema.europa.eu) | For directions, see [How to find us](#)

Follow us:    

This message and any attachment contain information which may be confidential or otherwise protected from disclosure. It is intended for the addressee(s) only and should not be relied upon as legal advice unless it is otherwise stated. If you are not the intended recipient(s) (or authorised by an addressee who received this message), access to this e-mail, or any disclosure or copying of its contents, or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you have received this e-mail in error, please inform the sender immediately.



Please consider the environment before printing this e-mail

---

Classified as internal/staff & contractors by the European Medicines Agency

**From:** Jakimiuk Marta  
**Sent:** Monday, 2 March 2026 10:16  
**To:** Tiiu Noobel <Tiiu.Noobel@mfa.ee>; Executive.Director <Executive.Director@ema.europa.eu>; Nominations <Nominations@ema.europa.eu>  
**Cc:** Jenas Kärolin <karolin.jenas@ravimiamet.ee>  
**Subject:** RE: Estonia - 2026-02-16 - Nomination invitation letter for CAT alternate

Dear Tiiu Noobel,

Apologies for the inconvenience, it was an error when converting few files into PDF at the same time. We will forward the correct letter as soon as possible.

Kind regards,

**Marta Jakimiuk**

Experts and Declarations of Interests Management  
Meeting Secretariat Office  
Committees and Quality Assurance Department



[European Medicines Agency](#)

Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Tel. +31 (0)88 781 8354

[ExpertsDB@ema.europa.eu](mailto:ExpertsDB@ema.europa.eu) | [www.ema.europa.eu](http://www.ema.europa.eu) | For directions, see [How to find us](#)

Follow us:    

This message and any attachment contain information which may be confidential or otherwise protected from disclosure. It is intended for the addressee(s) only and should not be relied upon as legal advice unless it is otherwise stated. If you are not the intended recipient(s) (or authorised by an addressee who received this message), access to this e-mail, or any disclosure or copying of its contents, or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you have received this e-mail in error, please inform the sender immediately.



Please consider the environment before printing this e-mail

---

**From:** Tiiu Noobel <[Tiiu.Noobel@mfa.ee](mailto:Tiiu.Noobel@mfa.ee)>

**Sent:** Monday, 2 March 2026 10:00

**To:** Executive.Director <[Executive.Director@ema.europa.eu](mailto:Executive.Director@ema.europa.eu)>; Nominations <[Nominations@ema.europa.eu](mailto:Nominations@ema.europa.eu)>

**Cc:** Jenas Kärolin <[karolin.jenas@ravimiamet.ee](mailto:karolin.jenas@ravimiamet.ee)>; Jakimiuk Marta <[marta.jakimiuk@ema.europa.eu](mailto:marta.jakimiuk@ema.europa.eu)>

**Subject:** FW: Estonia - 2026-02-16 - Nomination invitation letter for CAT alternate

Some people who received this message don't often get email from [tiiu.noobel@mfa.ee](mailto:tiiu.noobel@mfa.ee). [Learn why this is important](#)

Dear Executive Director,  
Dear Nomination Team,

I have not received an answer to my letter below, so I am sending it again. Is there a letter also for Estonia? This one is addressed to Latvia.

With best regards,

Tiiu Noobel

---

**From:** Tiiu Noobel

**Sent:** Monday, February 23, 2026 3:20 PM

**To:** 'marta.jakimiuk@ema.europa.eu' <[marta.jakimiuk@ema.europa.eu](mailto:marta.jakimiuk@ema.europa.eu)>

**Subject:** FW: Estonia - 2026-02-16 - Nomination invitation letter for CAT alternate

Dear Marta Jakimiuk,

Thank you but **the attached letter is about Latvia**. Is there letter also for Estonia?

With best regards,

Tiiu Noobel  
Secretary  
Permanent Representation of Estonia to the EU  
Rue Guimard 11/13, 1040 Brussels  
Tel: +32 2227 4337, [tiiu.noobel@mfa.ee](mailto:tiiu.noobel@mfa.ee)  
<https://eu.mfa.ee>

---

**From:** Esindus EL juures üldaadress <[permrep.eu@mfa.ee](mailto:permrep.eu@mfa.ee)>  
**Sent:** Monday, February 23, 2026 1:00 PM  
**To:** Tiiu Noobel <[Tiiu.Noobel@mfa.ee](mailto:Tiiu.Noobel@mfa.ee)>  
**Subject:** FW: Estonia - 2026-02-16 - Nomination invitation letter for CAT alternate

---

**From:** Jakimiuk Marta <[marta.jakimiuk@ema.europa.eu](mailto:marta.jakimiuk@ema.europa.eu)>  
**Sent:** Monday, February 23, 2026 12:31 PM  
**To:** Esindus EL juures üldaadress <[permrep.eu@mfa.ee](mailto:permrep.eu@mfa.ee)>  
**Cc:** Kompus Mairi <[mairi.kompus@ravimiamet.ee](mailto:mairi.kompus@ravimiamet.ee)>; Jenas Kärolin <[karolin.jenas@ravimiamet.ee](mailto:karolin.jenas@ravimiamet.ee)>; Saalik Pille <[pille.saalik@ravimiamet.ee](mailto:pille.saalik@ravimiamet.ee)>; Maimets Toivo <[toivo.maimets@ut.ee](mailto:toivo.maimets@ut.ee)>; Kiisk Katrin <[katrin.kiisk@ravimiamet.ee](mailto:katrin.kiisk@ravimiamet.ee)>; Nominations <[Nominations@ema.europa.eu](mailto:Nominations@ema.europa.eu)>  
**Subject:** Estonia - 2026-02-16 - Nomination invitation letter for CAT alternate

Your Excellency,

Please find attached a letter signed by the European Medicines Agency's Executive Director requesting the nomination of a representative to the Agency's Scientific Committees.

The letter is accompanied by:

- Annex B
- Committee composition and expertise

You are kindly invited to address nominations to the European Medicines Agency's Executive Director at [Executive.Director@ema.europa.eu](mailto:Executive.Director@ema.europa.eu) (with copy to [Nominations@ema.europa.eu](mailto:Nominations@ema.europa.eu)).

Please do not hesitate to contact me should you have any questions regarding this request for nomination.

***For the information of the National Competent Authority in cc of this email***

The nominee, **if not registered in Experts Management Tool**, will be required to register at: <https://experts.ema.europa.eu/>

- Registering in the Experts Management Tool, experts will be required to provide: Contact details and areas of expertise, Declaration of Interests, Curriculum Vitae. This should be completed with as much detail as possible.
- Instructions on how to register in the Experts Management Tool can be found in this user manual ([link](#)).

The EMA policy and guidance document can be found on the EMA website:

- European Medicines Agency policy on the handling of competing interests of scientific committees' members and experts ([link](#))
- Procedural guidance on inclusion of declared interests in the European Medicines Agency's declaration of interests (for scientific committees' members and experts) ([link](#))

Nominees will be subject to a pre-screening of any declared competing interest in line with the Agency's policy on handling of competing interests. In case of a negative outcome, the Agency will provide feedback of this screening to the nominating authority for subsequent consideration.

I would like to emphasize the importance of a timely nomination of a committee member to ensure the continuous representation of your Member State in the Committee. To avoid a vacant committee member position when an alternate position is already filled, you may consider nominating the alternate (temporarily) as member. Please also inform me if you intend to keep the position temporarily vacant. If no nomination is received, the position will be considered temporarily vacant until a nomination is received.

Sincerely yours,

**Marta Jakimiuk**

Experts and Declarations of Interests Management  
Meeting Secretariat Office  
Committees and Quality Assurance Department



[European Medicines Agency](#)

Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Tel. +31 (0)88 781 8354

[ExpertsDB@ema.europa.eu](mailto:ExpertsDB@ema.europa.eu) | [www.ema.europa.eu](http://www.ema.europa.eu) | For directions, see [How to find us](#)

Follow us:    

This message and any attachment contain information which may be confidential or otherwise protected from disclosure. It is intended for the addressee(s) only and should not be relied upon as legal advice unless it is otherwise stated. If you are not the intended recipient(s) (or authorised by an addressee who received this message), access to this e-mail, or any disclosure or copying of its contents, or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you have received this e-mail in error, please inform the sender immediately.

 Please consider the environment before printing this e-mail

Classified as internal/staff & contractors by the European Medicines Agency